CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PGS1 (ImmuneEditome ID:9489)

1. Gene summary of enriched editing regions for PGS1

check button Gene summary
Gene informationGene symbol

PGS1

Gene ID

9489

GeneSynonyms-
GeneCytomap

17q25.3

GeneTypeprotein-coding
GeneDescriptionCDP-diacylglycerol--glycerol-3-phosphate 3-phosphatidyltransferase, mitochondrial|PGP synthase 1
GeneModificationdate20230517
UniprotIDQ32NB8;K7EQF5;U3KQD9;K7EQ89;K7EL44
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:78422549-78423041:+ENST00000586880.1ENSG00000087157.17PGS1ncRNA_intronicAluJb,AluSq2chr17:78422549-78423041:+.alignment
chr17:78422549-78423041:+ENST00000588281.4ENSG00000087157.17PGS1ncRNA_intronicAluJb,AluSq2chr17:78422549-78423041:+.alignment


Top

2. Tumor-specific enriched editing regions for PGS1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000087157.17,PGS1BRCAEAG1.8607e-08image
chr17:78422549-78423041:+LUADEER2.9603e-04image
ENSG00000087157.17,PGS1LUADEAG2.9913e-04image
chr17:78422549-78423041:+LUSCEER1.2746e-07image
ENSG00000087157.17,PGS1LUSCEAG1.4028e-11image
chr17:78422549-78423041:+THCAEER1.2476e-03image
ENSG00000087157.17,PGS1THCAEAG6.0106e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000087157.17,PGS1BLCAPathEAG1.0674e-033.4962e-040.2100image
chr17:78422549-78423041:+BLCAPathEER8.2798e-045.1545e-040.2081image
ENSG00000087157.17,PGS1KIRPPathEAG2.6070e-021.9342e-020.1641image
chr17:78422549-78423041:+KIRPPathEER1.8914e-021.6455e-020.1686image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for PGS1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:78422549-78423041:+LAMLEERENSG00000270388,RP11-475J5.80.33804.3739e-027.1895e-080.4319imageNNNAEosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr17:78422549-78423041:+PAADEERENSG00000272009,RP1-313I6.120.34825.3562e-032.4661e-080.4441imageNNNANK_cells_restingGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
chr17:78422549-78423041:+PAADEERENSG00000175197,DDIT30.32576.5212e-038.3126e-080.4287imageNNDDIT3NK_cells_restingGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
chr17:78422549-78423041:+PAADEERENSG00000197279,ZNF1650.28093.3776e-025.0312e-080.4351imageNNNANK_cells_restingGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
chr17:78422549-78423041:+THYMEERENSG00000077150,NFKB20.33431.8057e-021.2265e-040.4002imageNNNFKB2T_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr17:78422549-78423041:+THYMEERENSG00000215788,TNFRSF250.29983.3595e-022.0681e-050.4394imageNNTNFRSF25T_cells_CD4_memory_activatedGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr17:78422549-78423041:+THYMEERENSG00000212588,SNORA260.29014.2688e-021.1558e-040.4016imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_KRAS_SIGNALING_DN
chr17:78422549-78423041:+LAMLEERENSG00000270388,RP11-475J5.80.33804.3739e-027.1895e-080.4319imageNNNAEosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr17:78422549-78423041:+PAADEERENSG00000272009,RP1-313I6.120.34825.3562e-032.4661e-080.4441imageNNNANK_cells_restingGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
chr17:78422549-78423041:+PAADEERENSG00000175197,DDIT30.32576.5212e-038.3126e-080.4287imageNNDDIT3NK_cells_restingGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
chr17:78422549-78423041:+PAADEERENSG00000197279,ZNF1650.28093.3776e-025.0312e-080.4351imageNNNANK_cells_restingGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
chr17:78422549-78423041:+THYMEERENSG00000077150,NFKB20.33431.8057e-021.2265e-040.4002imageNNNFKB2T_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr17:78422549-78423041:+THYMEERENSG00000215788,TNFRSF250.29983.3595e-022.0681e-050.4394imageNNTNFRSF25T_cells_CD4_memory_activatedGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr17:78422549-78423041:+THYMEERENSG00000212588,SNORA260.29014.2688e-021.1558e-040.4016imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_KRAS_SIGNALING_DN

More results



Top

4. Enriched editing regions and immune related splicing for PGS1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000087157.17,PGS1
GBMEAGIRENSG00000099821.9chr19617569:617870:618487:618586-0.31609.7042e-034.2403e-06-0.4075imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_PEROXISOME
chr17:78422549-78423041:+
GBMEERIRENSG00000215021.4chr126969955:6970068:6970195:6970280-0.26474.5123e-022.9064e-05-0.4014imageNNNAMacrophages_M2GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr17:78422549-78423041:+
GBMEERIRENSG00000174791.6chr1166333918:66335498:66335609:66335682-0.38076.8246e-042.3431e-06-0.4094imageNNRIN1T_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
chr17:78422549-78423041:+
GBMEERIRENSG00000099821.9chr19617569:617870:618487:618586-0.33593.5720e-032.0506e-06-0.4211imageNNNAMonocytesGSVA_HALLMARK_PEROXISOME
ENSG00000087157.17,PGS1
GBMEAGIRENSG00000174791.6chr1166333918:66335498:66335609:66335682-0.37479.7895e-047.7092e-07-0.4268imageNBUD13;CPSF6;CSTF2T;DKC1;EIF4A3;FAM120A;FBL;FKBP4;FUS;GTF2F1;HNRNPA1;HNRNPK;IGF2BP1;IGF2BP2;IGF2BP3;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF9;TAF15;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1RIN1T_cells_follicular_helperGSVA_HALLMARK_PEROXISOME
ENSG00000087157.17,PGS1
PAADEAGESENSG00000166797.6chr1564075491:64075537:64081101:64081151:64088686:64088851-0.37352.3990e-025.1832e-08-0.4334imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_BILE_ACID_METABOLISM
ENSG00000087157.17,PGS1
PAADEAGESENSG00000138709.13chr4128091000:128091144:128091346:128091512:128098185:128098330-0.26993.5605e-021.8023e-06-0.4183imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP7;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NANK_cells_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr17:78422549-78423041:+
TGCTEERA5ENSG00000160392.9chr1940336319:40336407:40341838:40341885:40341785:40341885-0.38307.3596e-047.5740e-06-0.4040imageNNNAB_cells_naiveGSVA_HALLMARK_MYOGENESIS
ENSG00000087157.17,PGS1
TGCTEAGA5ENSG00000160392.9chr1940336319:40336407:40341838:40341885:40341785:40341885-0.40721.5396e-043.0811e-06-0.4177imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184NAB_cells_naiveGSVA_HALLMARK_MYOGENESIS
ENSG00000087157.17,PGS1
TGCTEAGESENSG00000110958.11chr1256664775:56664800:56670274:56670364:56671748:56671809-0.38872.6006e-045.3957e-06-0.4167imageNACIN1;ADAR;AIFM1;ALKBH5;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;RTCB;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184PTGES3

More results



Top

5. Enriched editing regions and immune infiltration for PGS1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:78422549-78423041:+BLCAEERT_cells_CD4_memory_activated1.2077e-040.2298image
ENSG00000087157.17,PGS1BLCAEAGT_cells_CD4_memory_activated5.4930e-040.2031image
ENSG00000087157.17,PGS1BRCAEAGT_cells_CD4_memory_activated2.5837e-020.0768image
chr17:78422549-78423041:+CESCEERNK_cells_resting2.2258e-030.2200image
ENSG00000087157.17,PGS1CESCEAGNK_cells_resting3.6063e-030.2080image
chr17:78422549-78423041:+CHOLEERNK_cells_activated1.8493e-020.4585image
ENSG00000087157.17,PGS1CHOLEAGNK_cells_activated1.6065e-020.4674image
chr17:78422549-78423041:+COADEERNK_cells_activated3.1826e-020.1720image
chr17:78422549-78423041:+DLBCEERNK_cells_activated4.1985e-020.4016image
ENSG00000087157.17,PGS1DLBCEAGNK_cells_activated4.2602e-020.3930image
chr17:78422549-78423041:+ESCAEERT_cells_regulatory_(Tregs)2.1413e-02-0.1841image
ENSG00000087157.17,PGS1ESCAEAGT_cells_regulatory_(Tregs)9.6862e-03-0.2065image
chr17:78422549-78423041:+HNSCEERB_cells_memory2.0456e-020.1713image
chr17:78422549-78423041:+KIRCEERT_cells_gamma_delta2.0552e-020.1428image
ENSG00000087157.17,PGS1KIRCEAGT_cells_gamma_delta4.6489e-040.2116image
chr17:78422549-78423041:+KIRPEERT_cells_CD84.6682e-030.1880image
ENSG00000087157.17,PGS1KIRPEAGT_cells_CD85.2856e-030.1850image
ENSG00000087157.17,PGS1LAMLEAGDendritic_cells_activated3.3378e-020.1774image
chr17:78422549-78423041:+LGGEERDendritic_cells_activated7.3569e-040.1560image
ENSG00000087157.17,PGS1LGGEAGDendritic_cells_activated1.5046e-040.1745image
chr17:78422549-78423041:+LIHCEERMacrophages_M19.5080e-030.3531image
ENSG00000087157.17,PGS1LIHCEAGMacrophages_M11.0854e-030.4149image
ENSG00000087157.17,PGS1LUADEAGT_cells_CD4_memory_activated4.2593e-020.1011image
chr17:78422549-78423041:+LUSCEERNK_cells_activated4.9259e-020.0973image
ENSG00000087157.17,PGS1LUSCEAGNK_cells_activated1.3675e-020.1202image
ENSG00000087157.17,PGS1MESOEAGEosinophils3.3480e-020.2773image
chr17:78422549-78423041:+OVEERMacrophages_M22.5679e-03-0.1911image
ENSG00000087157.17,PGS1OVEAGMacrophages_M22.2538e-03-0.1927image
chr17:78422549-78423041:+PAADEERMacrophages_M02.8908e-030.2466image
ENSG00000087157.17,PGS1PAADEAGMacrophages_M01.9385e-030.2553image
ENSG00000087157.17,PGS1PCPGEAGEosinophils3.3962e-020.1954image
chr17:78422549-78423041:+PRADEERB_cells_memory2.3228e-020.1735image
ENSG00000087157.17,PGS1PRADEAGT_cells_CD4_memory_activated6.9640e-03-0.1999image
chr17:78422549-78423041:+SARCEERB_cells_naive1.3759e-02-0.1956image
ENSG00000087157.17,PGS1SARCEAGB_cells_naive3.4884e-02-0.1659image
chr17:78422549-78423041:+SKCMEERT_cells_regulatory_(Tregs)3.0912e-02-0.1279image
ENSG00000087157.17,PGS1SKCMEAGT_cells_regulatory_(Tregs)1.9773e-02-0.1341image
chr17:78422549-78423041:+STADEERB_cells_memory4.2563e-03-0.1817image
ENSG00000087157.17,PGS1STADEAGMacrophages_M23.2052e-030.1804image
chr17:78422549-78423041:+THCAEERT_cells_CD4_memory_activated1.8264e-020.1184image
ENSG00000087157.17,PGS1THCAEAGT_cells_CD4_memory_activated9.3218e-030.1281image
chr17:78422549-78423041:+THYMEERDendritic_cells_resting4.1969e-03-0.3040image
ENSG00000087157.17,PGS1THYMEAGDendritic_cells_resting1.9821e-02-0.2494image
chr17:78422549-78423041:+UCECEERNeutrophils3.8925e-030.2821image
ENSG00000087157.17,PGS1UCECEAGT_cells_gamma_delta3.8013e-020.2000image
chr17:78422549-78423041:+UVMEEREosinophils2.2963e-030.4987image
ENSG00000087157.17,PGS1UVMEAGT_cells_gamma_delta2.0455e-030.5035image


Top

6. Enriched editing regions and immune gene sets for PGS1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr17:78422549-78423041:+BLCAEER1.5064e-050.25775.8857e-030.16578.1757e-050.23531.6216e-050.2568image
ENSG00000087157.17,PGS1BLCAEAG1.7696e-050.25086.2031e-030.16151.5070e-040.22239.3320e-050.2290image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr17:78422549-78423041:+BLCAGSVA_HALLMARK_GLYCOLYSISEER1.1845e-060.2880image
ENSG00000087157.17,PGS1BLCAGSVA_HALLMARK_GLYCOLYSISEAG1.7386e-060.2784image
ENSG00000087157.17,PGS1BRCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.6023e-040.1298image
chr17:78422549-78423041:+CESCGSVA_HALLMARK_MITOTIC_SPINDLEEER4.7103e-03-0.2037image
ENSG00000087157.17,PGS1CESCGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.8020e-03-0.2069image
chr17:78422549-78423041:+CHOLGSVA_HALLMARK_BILE_ACID_METABOLISMEER4.6410e-02-0.3940image
ENSG00000087157.17,PGS1COADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.7580e-02-0.1550image
ENSG00000087157.17,PGS1DLBCGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG5.0883e-030.5234image
chr17:78422549-78423041:+DLBCGSVA_HALLMARK_FATTY_ACID_METABOLISMEER2.6517e-030.5647image
ENSG00000087157.17,PGS1ESCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG4.2771e-030.2276image
chr17:78422549-78423041:+ESCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER5.6547e-030.2206image
ENSG00000087157.17,PGS1GBMGSVA_HALLMARK_ADIPOGENESISEAG5.5021e-040.2874image
chr17:78422549-78423041:+GBMGSVA_HALLMARK_ADIPOGENESISEER1.6953e-030.2630image
ENSG00000087157.17,PGS1HNSCGSVA_HALLMARK_DNA_REPAIREAG1.0708e-02-0.1745image
chr17:78422549-78423041:+HNSCGSVA_HALLMARK_DNA_REPAIREER5.5527e-03-0.2042image
chr17:78422549-78423041:+KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.9462e-020.1271image
chr17:78422549-78423041:+LAMLGSVA_HALLMARK_P53_PATHWAYEER1.5693e-03-0.2620image
ENSG00000087157.17,PGS1LAMLGSVA_HALLMARK_SPERMATOGENESISEAG7.6660e-030.2214image
ENSG00000087157.17,PGS1LGGGSVA_HALLMARK_SPERMATOGENESISEAG1.7072e-03-0.1448image
chr17:78422549-78423041:+LGGGSVA_HALLMARK_SPERMATOGENESISEER1.1637e-02-0.1169image
ENSG00000087157.17,PGS1LIHCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG3.1169e-02-0.2809image
chr17:78422549-78423041:+LIHCGSVA_HALLMARK_HEME_METABOLISMEER2.9990e-02-0.2984image
chr17:78422549-78423041:+LUADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER8.0615e-040.1671image
ENSG00000087157.17,PGS1LUADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG4.2192e-050.2025image
chr17:78422549-78423041:+LUSCGSVA_HALLMARK_GLYCOLYSISEER3.1370e-030.1457image
ENSG00000087157.17,PGS1LUSCGSVA_HALLMARK_GLYCOLYSISEAG2.8061e-030.1455image
chr17:78422549-78423041:+OVGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.9197e-040.2286image
ENSG00000087157.17,PGS1OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.3713e-030.2018image
ENSG00000087157.17,PGS1PAADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.1444e-040.3149image
chr17:78422549-78423041:+PAADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER8.1550e-050.3223image
ENSG00000087157.17,PGS1PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG7.7133e-03-0.2442image
chr17:78422549-78423041:+PCPGGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.8795e-02-0.2188image
ENSG00000087157.17,PGS1PRADGSVA_HALLMARK_DNA_REPAIREAG7.9262e-040.2472image
chr17:78422549-78423041:+PRADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER7.9276e-03-0.2024image
ENSG00000087157.17,PGS1READGSVA_HALLMARK_MYC_TARGETS_V2EAG1.0382e-02-0.3559image
chr17:78422549-78423041:+READGSVA_HALLMARK_MYC_TARGETS_V2EER1.4459e-02-0.3439image
ENSG00000087157.17,PGS1SARCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.6735e-030.2344image
chr17:78422549-78423041:+SARCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.9812e-030.2224image
ENSG00000087157.17,PGS1SKCMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG5.7906e-050.2292image
chr17:78422549-78423041:+SKCMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER8.4845e-040.1966image
ENSG00000087157.17,PGS1STADGSVA_HALLMARK_ADIPOGENESISEAG2.5002e-020.1377image
chr17:78422549-78423041:+STADGSVA_HALLMARK_ADIPOGENESISEER1.1994e-020.1600image
chr17:78422549-78423041:+TGCTGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER2.6761e-02-0.1966image
ENSG00000087157.17,PGS1TGCTGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.6574e-020.2115image
chr17:78422549-78423041:+THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.1823e-030.1534image
ENSG00000087157.17,PGS1THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.0232e-020.1265image
chr17:78422549-78423041:+THYMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.8482e-020.2521image
ENSG00000087157.17,PGS1THYMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG7.8873e-030.2831image
chr17:78422549-78423041:+UCECGSVA_HALLMARK_E2F_TARGETSEER1.4955e-02-0.2392image
ENSG00000087157.17,PGS1UCECGSVA_HALLMARK_E2F_TARGETSEAG7.2302e-03-0.2571image
chr17:78422549-78423041:+UCSGSVA_HALLMARK_APOPTOSISEER2.1622e-030.4655image
ENSG00000087157.17,PGS1UCSGSVA_HALLMARK_APOPTOSISEAG1.3234e-030.4792image


Top

7. Enriched editing regions and drugs for PGS1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000087157.17,PGS1ACCGDC.0449EAG2.0719e-020.5130image
chr17:78422549-78423041:+BLCACCT007093EER5.4786e-060.2702image
ENSG00000087157.17,PGS1BLCACCT007093EAG2.9145e-060.2725image
ENSG00000087157.17,PGS1BRCACHIR.99021EAG9.1919e-040.1142image
chr17:78422549-78423041:+CESCCEP.701EER2.3489e-04-0.2632image
ENSG00000087157.17,PGS1CESCCEP.701EAG3.3986e-04-0.2546image
ENSG00000087157.17,PGS1CHOLBleomycinEAG7.5584e-04-0.6186image
chr17:78422549-78423041:+CHOLBleomycinEER2.3222e-04-0.6617image
chr17:78422549-78423041:+DLBCElesclomolEER9.7981e-03-0.4970image
ENSG00000087157.17,PGS1DLBCElesclomolEAG1.4398e-02-0.4656image
ENSG00000087157.17,PGS1ESCABMS.536924EAG4.2508e-03-0.2277image
chr17:78422549-78423041:+ESCABMS.536924EER1.3835e-02-0.1967image
ENSG00000087157.17,PGS1GBMBosutinibEAG1.3936e-030.2666image
chr17:78422549-78423041:+GBMBosutinibEER9.1243e-040.2772image
ENSG00000087157.17,PGS1HNSCGDC.0449EAG6.8701e-030.1847image
chr17:78422549-78423041:+HNSCGDC.0449EER3.3813e-020.1570image
ENSG00000087157.17,PGS1KIRCBicalutamideEAG1.1005e-020.1545image
chr17:78422549-78423041:+KIRCCI.1040EER4.6819e-03-0.1739image
chr17:78422549-78423041:+KIRPBexaroteneEER4.6237e-030.1882image
ENSG00000087157.17,PGS1KIRPGSK.650394EAG4.8725e-030.1867image
ENSG00000087157.17,PGS1LAMLFTI.277EAG7.0863e-030.2235image
chr17:78422549-78423041:+LAMLCisplatinEER6.3047e-03-0.2274image
chr17:78422549-78423041:+LGGJNK.Inhibitor.VIIIEER3.3434e-040.1656image
ENSG00000087157.17,PGS1LGGJNK.Inhibitor.VIIIEAG7.0768e-050.1828image
chr17:78422549-78423041:+LUADDoxorubicinEER4.2658e-05-0.2034image
ENSG00000087157.17,PGS1LUADDoxorubicinEAG1.4376e-04-0.1883image
ENSG00000087157.17,PGS1LUSCBicalutamideEAG3.9531e-03-0.1403image
chr17:78422549-78423041:+LUSCBicalutamideEER2.0070e-02-0.1149image
ENSG00000087157.17,PGS1MESOGefitinibEAG2.6878e-02-0.2882image
chr17:78422549-78423041:+OVBexaroteneEER3.7468e-040.2246image
ENSG00000087157.17,PGS1OVDMOGEAG3.5370e-050.2589image
chr17:78422549-78423041:+PAADBX.795EER8.4009e-040.2753image
ENSG00000087157.17,PGS1PAADBX.795EAG3.8755e-040.2908image
ENSG00000087157.17,PGS1PCPGMG.132EAG9.3584e-040.3008image
chr17:78422549-78423041:+PCPGMG.132EER1.9238e-030.2863image
ENSG00000087157.17,PGS1PRADAZ628EAG9.6350e-05-0.2858image
chr17:78422549-78423041:+PRADAZ628EER1.6072e-03-0.2395image
ENSG00000087157.17,PGS1READCMKEAG9.7899e-030.3585image
chr17:78422549-78423041:+READCMKEER3.5331e-020.2984image
ENSG00000087157.17,PGS1SARCAG.014699EAG7.7524e-060.3433image
chr17:78422549-78423041:+SARCAG.014699EER5.1274e-060.3538image
chr17:78422549-78423041:+SKCMGefitinibEER5.5173e-030.1643image
ENSG00000087157.17,PGS1SKCMGefitinibEAG2.0187e-030.1773image
chr17:78422549-78423041:+STADABT.888EER8.1305e-050.2486image
ENSG00000087157.17,PGS1STADABT.888EAG2.5641e-030.1845image
ENSG00000087157.17,PGS1TGCTAUY922EAG4.2545e-020.1796image
chr17:78422549-78423041:+THCAEmbelinEER4.9032e-070.2492image
ENSG00000087157.17,PGS1THCAEmbelinEAG5.0885e-060.2228image
chr17:78422549-78423041:+THYMAICAREER4.6278e-03-0.3009image
ENSG00000087157.17,PGS1THYMAICAREAG8.9152e-03-0.2788image
chr17:78422549-78423041:+UCECMidostaurinEER2.8679e-030.2910image
ENSG00000087157.17,PGS1UCECMidostaurinEAG3.6818e-030.2772image
chr17:78422549-78423041:+UCSJNK.9LEER1.1313e-040.5664image
ENSG00000087157.17,PGS1UCSJNK.9LEAG2.5839e-040.5354image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType